On November 10, 2025, Telix Pharmaceuticals Ltd. was sued for violations of the federal securities laws in the United States District Court for the Southern District of Indiana on behalf of investors who purchased or otherwise
acquired publicly traded Telix securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.